Abnormal activity of SRPKs, mostly SRPK1 and SRPK2, has been found in different cancer types (Gammons et al., 2014; Siqueira et al., 2015; van Roosmalen et al., 2015; Bullock et al., 2016; Gong et al., 2016; Sigala et al., 2016; Zhuo et al., 2018), where they act in cellular processes related to tumor development and metastasis, such as angiogenesis (Gammons et al., 2014), epithelial-mesenchymal transition (EMT) (Wang et al., 2017), and cell migration (van Roosmalen et al., 2015; Wang et al., 2016). This evidence concerns the gene SRPK1 and neoplasm.